HK1200842A1 - 具有改進半衰期和其他特性的蛋白質 - Google Patents

具有改進半衰期和其他特性的蛋白質

Info

Publication number
HK1200842A1
HK1200842A1 HK15101137.5A HK15101137A HK1200842A1 HK 1200842 A1 HK1200842 A1 HK 1200842A1 HK 15101137 A HK15101137 A HK 15101137A HK 1200842 A1 HK1200842 A1 HK 1200842A1
Authority
HK
Hong Kong
Prior art keywords
proteins
life
properties
improved half
improved
Prior art date
Application number
HK15101137.5A
Other languages
English (en)
Inventor
Michael March Schmidt
Eric Steven Furfine
Amy Jada Andreucci
Thomas M Barnes
Original Assignee
Eleven Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eleven Biotherapeutics Inc filed Critical Eleven Biotherapeutics Inc
Publication of HK1200842A1 publication Critical patent/HK1200842A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
HK15101137.5A 2011-11-18 2015-02-03 具有改進半衰期和其他特性的蛋白質 HK1200842A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161561785P 2011-11-18 2011-11-18
US201161576491P 2011-12-16 2011-12-16
US201261710476P 2012-10-05 2012-10-05
PCT/US2012/065733 WO2013075066A2 (en) 2011-11-18 2012-11-18 Proteins with improved half-life and other properties

Publications (1)

Publication Number Publication Date
HK1200842A1 true HK1200842A1 (zh) 2015-08-14

Family

ID=47295197

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15101137.5A HK1200842A1 (zh) 2011-11-18 2015-02-03 具有改進半衰期和其他特性的蛋白質

Country Status (4)

Country Link
US (2) US20140315817A1 (zh)
EP (1) EP2780364A2 (zh)
HK (1) HK1200842A1 (zh)
WO (1) WO2013075066A2 (zh)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2396347B1 (en) 2009-02-11 2017-04-12 Albumedix A/S Albumin variants and conjugates
CN102741280B (zh) 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 白蛋白变体
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
US9238080B2 (en) 2010-05-21 2016-01-19 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
KR20230156435A (ko) 2010-07-09 2023-11-14 바이오버라티브 테라퓨틱스 인크. 인자 iｘ 폴리펩티드 및 이들의 사용 방법
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
AU2013234299B2 (en) 2012-03-16 2017-06-22 Albumedix Ltd. Albumin variants
GB2512156A (en) 2012-11-08 2014-09-24 Novozymes Biopharma Dk As Albumin variants
AU2014228938B2 (en) 2013-03-15 2019-05-02 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations
EP3063171B1 (en) 2013-11-01 2019-07-24 University Of Oslo Albumin variants and uses thereof
TW201609812A (zh) 2014-07-31 2016-03-16 安美基研究（慕尼黑）公司 最佳化之跨物種特異性雙特異性單鏈抗體構築體
DK3180018T3 (da) 2014-08-12 2019-10-28 Massachusetts Inst Technology Synergistisk tumorbehandling med IL-2 og integrinbindende Fc-fusionsprotein
US20170216403A1 (en) 2014-08-12 2017-08-03 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
WO2016061149A1 (en) * 2014-10-14 2016-04-21 Medgenics Medical Israel Ltd. Genetically-modified micro-organ secreting a therapeutic peptide and methods of use thereof
MX2017013348A (es) 2015-04-17 2018-08-01 Amgen Res Munich Gmbh Construcciones de anticuerpos biespecificos contra cdh3 y cd3.
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TW202346349A (zh) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
JP7007261B2 (ja) 2015-08-20 2022-01-24 アルブミディクス リミティド アルブミン変異体及びコンジュゲート
ES2863278T3 (es) 2015-10-02 2021-10-11 Silver Creek Pharmaceuticals Inc Proteínas terapéuticas biespecíficas para la reparación de tejidos
BR112018012851A2 (pt) 2015-12-22 2018-12-26 Albumedix Ltd cepas de expressão de proteína melhoradas
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
WO2017214945A1 (zh) * 2016-06-16 2017-12-21 毛侃琅 提升Hepcidin基因表达水平的慢病毒表达载体及其应用
WO2018082758A1 (en) 2016-11-04 2018-05-11 Aarhus Universitet Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
AU2018207303A1 (en) 2017-01-10 2019-07-25 xCella Biosciences, Inc. Combination tumor treatment with an integrin-binding-Fc fusion protein and immune modulator
CA3056630A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
CA3064435A1 (en) 2017-05-24 2018-11-29 Pandion Therapeutics, Inc. Targeted immunotolerance
AU2018286919B2 (en) 2017-06-20 2022-10-06 Albumedix Ltd. Improved protein expression strains
EP3661954B1 (en) 2017-08-03 2022-02-09 Amgen Inc. Interleukin-21 muteins and methods of treatment
US11485781B2 (en) 2017-08-17 2022-11-01 Massachusetts Institute Of Technology Multiple specificity binders of CXC chemokines
ES2928576T3 (es) 2017-09-08 2022-11-21 Amgen Inc Inhibidores de KRAS G12C y métodos de uso de los mismos
WO2019075519A1 (en) * 2017-10-18 2019-04-25 Csl Limited HUMAN SERUM ALBUMIN VARIANTS AND USES THEREOF
BR112020010514A2 (pt) 2017-11-29 2020-11-24 Csl Limited método para tratar ou prevenir lesão por isquemia-reperfusão
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
CR20210319A (es) 2018-01-12 2021-07-27 Amgen Inc ANTICUERPOS ANTI-PD-1 Y MÉTODOS DE TRATAMIENTO (Div. 2020-330)
CA3089784A1 (en) 2018-02-12 2019-08-15 Biontech Rna Pharmaceuticals Gmbh Treatment using cytokine encoding rna
US20210238238A1 (en) 2018-05-16 2021-08-05 Csl Limited Soluble complement receptor type i variants and uses thereof
CA3106858A1 (en) 2018-07-24 2020-01-30 Biontech Rna Pharmaceuticals Gmbh Il2 agonists
MX2021001353A (es) 2018-08-03 2021-04-13 Amgen Res Munich Gmbh Constructos de anticuerpos para cldn18.2 y cd3.
AU2019336940A1 (en) 2018-09-06 2021-03-11 Bavarian Nordic A/S Storage improved poxvirus compositions
KR20210068478A (ko) 2018-09-28 2021-06-09 메사추세츠 인스티튜트 오브 테크놀로지 콜라겐-국재화된 면역조정성 분자 및 그의 방법
WO2020154032A1 (en) 2019-01-23 2020-07-30 Massachusetts Institute Of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
MX2021009506A (es) 2019-02-08 2021-09-08 Biontech Cell & Gene Therapies Gmbh Tratamiento que implica celulas t modificadas con car y citoquinas.
KR20210143759A (ko) 2019-03-18 2021-11-29 비온테크 쎌 & 제네 테라피스 게엠베하 면역 작용 세포의 특이적 활성화를 위한 인터루킨-2 수용체 (il2r) 및 인터루킨-2 (il2) 변이체
WO2020200481A1 (en) 2019-04-05 2020-10-08 Biontech Rna Pharmaceuticals Gmbh Treatment involving interleukin-2 (il2) and interferon (ifn)
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
TW202115105A (zh) 2019-06-24 2021-04-16 德商拜恩迪克Ｒｎａ製藥有限公司 Ｉｌ２激動劑
US11642409B2 (en) 2019-06-26 2023-05-09 Massachusetts Insttute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
WO2021058091A1 (en) 2019-09-24 2021-04-01 Biontech Rna Pharmaceuticals Gmbh Treatment involving therapeutic antibody and interleukin-2 (il2)
EP3819007A1 (en) 2019-11-11 2021-05-12 Amgen Research (Munich) GmbH Dosing regimen for anti-bcma agents
EP4069200A1 (en) 2019-12-04 2022-10-12 Albumedix Ltd Methods and compositions produced thereby
WO2021129927A1 (en) 2019-12-23 2021-07-01 Biontech Cell & Gene Therapies Gmbh Treatment with immune effector cells engineered to express an antigen receptor
WO2021129945A1 (en) 2019-12-27 2021-07-01 Biontech Cell & Gene Therapies Gmbh In vitro and in vivo gene delivery to immune effector cells using nanoparticles functionalized with designed ankyrin repeat proteins (darpins)
US20230093169A1 (en) 2020-01-22 2023-03-23 Amgen Research (Munch) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
WO2021183861A1 (en) 2020-03-12 2021-09-16 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
WO2021180943A1 (en) 2020-03-12 2021-09-16 Bavarian Nordic A/S Compositions improving poxvirus stability
CA3171370A1 (en) 2020-03-16 2021-09-23 Ugur Sahin Antigen-specific t cell receptors and t cell epitopes
WO2021197589A1 (en) 2020-03-31 2021-10-07 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination
EP4153633A1 (en) 2020-05-19 2023-03-29 Amgen Inc. Mageb2 binding constructs
US20230303646A1 (en) * 2020-08-19 2023-09-28 Energesis Pharmaceuticals, Inc. Analogs of human fibroblast growth factors
EP4208480A2 (en) 2020-09-04 2023-07-12 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding protein constructs with human serum albumin domains
AU2021345124A1 (en) 2020-09-16 2023-03-30 Amgen Inc. Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer
BR112023008629A2 (pt) 2020-11-06 2023-10-03 Amgen Inc Construtos de polipeptídeos que se ligam seletivamente a cldn6 e cd3
TW202233678A (zh) 2020-11-06 2022-09-01 德商安美基研究（慕尼黑）公司 具有增強的剪切特徵的多肽
BR112023008670A2 (pt) 2020-11-06 2024-02-06 Amgen Inc Construtos polipeptídicos ligados à cd3
CN116829192A (zh) * 2020-11-10 2023-09-29 纽约大学 大型胞饮作用选择性单体-药物缀合物
TW202233682A (zh) 2020-11-10 2022-09-01 美商安進公司 用於投與ＢＣＭＡｘＣＤ３結合分子之方法
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022218891A2 (en) 2021-04-12 2022-10-20 BioNTech SE Rna compositions comprising a buffer substance and methods for preparing, storing and using the same
BR112023021654A2 (pt) 2021-04-20 2023-12-26 BioNTech SE Vacina contra vírus
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
CA3235180A1 (en) 2021-10-21 2023-04-27 BioNTech SE Coronavirus vaccine
EP4238577A3 (en) 2021-10-22 2023-12-06 BioNTech SE Compositions for administration of different doses of rna
WO2023083434A1 (en) 2021-11-09 2023-05-19 BioNTech SE Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection
WO2023126053A1 (en) 2021-12-28 2023-07-06 BioNTech SE Lipid-based formulations for administration of rna
WO2023165681A1 (en) 2022-03-01 2023-09-07 BioNTech SE Rna lipid nanoparticles (lnps) comprising a polyoxazoline and/or polyoxazine polymer
WO2023193892A1 (en) 2022-04-05 2023-10-12 BioNTech SE Nucleic acid compositions comprising an inorganic polyphosphate and methods for preparing, storing and using the same
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024017479A1 (en) 2022-07-21 2024-01-25 BioNTech SE Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production
WO2024028325A1 (en) 2022-08-01 2024-02-08 BioNTech SE Nucleic acid compositions comprising amphiphilic oligo ethylene glycol (oeg)-conjugated compounds and methods of using such compounds and compositions
WO2024027910A1 (en) 2022-08-03 2024-02-08 BioNTech SE Rna for preventing or treating tuberculosis
WO2024028445A1 (en) 2022-08-03 2024-02-08 BioNTech SE Rna for preventing or treating tuberculosis
WO2024077044A1 (en) 2022-10-05 2024-04-11 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
WO2024089258A1 (en) 2022-10-28 2024-05-02 Aarhus Universitet Albumin conjugated to cpg oligodeoxynucleotides as super-boosters of immune response

Family Cites Families (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625041A (en) 1990-09-12 1997-04-29 Delta Biotechnology Limited Purification of proteins
GB9019919D0 (en) 1990-09-12 1990-10-24 Delta Biotechnology Ltd Purification of proteins
US2714586A (en) 1951-06-25 1955-08-02 Phillips Petroleum Co Washing urea and thiourea containing adducts
US4302386A (en) 1978-08-25 1981-11-24 The Ohio State University Antigenic modification of polypeptides
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
JPS60169498A (ja) 1984-02-10 1985-09-02 Kyowa Hakko Kogyo Co Ltd 成人ｔ細胞白血病ウイルス抗原ペプチド誘導体
US4868112A (en) 1985-04-12 1989-09-19 Genetics Institute, Inc. Novel procoagulant proteins
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
WO1988008027A1 (en) 1987-04-09 1988-10-20 Delta Biotechnology Limited Yeast vector
EP0305216B1 (en) 1987-08-28 1995-08-02 Novo Nordisk A/S Recombinant Humicola lipase and process for the production of recombinant humicola lipases
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
IL88326A (en) 1987-11-18 1993-03-15 Gist Brocades Nv Purification of serum albumin
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8909916D0 (en) 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8927722D0 (en) 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
DE4000939A1 (de) 1990-01-15 1991-07-18 Brem Gottfried Prof Dr Dr Verfahren zur antikoerpergewinnung
JP3230091B2 (ja) 1990-06-25 2001-11-19 ウェルファイド株式会社 ヒト血清アルブミンの着色抑制方法
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2058820C (en) 1991-04-25 2003-07-15 Kotikanyad Sreekrishna Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5298418A (en) 1991-09-16 1994-03-29 Boyce Thompson Institute For Plant Research, Inc. Cell line isolated from larval midgut tissue of Trichoplusia ni
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
DE4226971C2 (de) 1992-08-14 1997-01-16 Widmar Prof Dr Tanner Modifizierte Pilzzellen und Verfahren zur Herstellung rekombinanter Produkte
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
EP0710283A4 (en) 1993-07-22 1997-07-02 Merck & Co Inc THE EXPRESSION OF HUMAN INTERLEUKIN-1-g (b) IN A TRANSGENIC ANIMAL
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US6811773B1 (en) 1993-12-22 2004-11-02 Human Genome Sciences, Inc. Human monocyte colony inhibitory factor (M-CIF) polypeptides
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
GB9404270D0 (en) 1994-03-05 1994-04-20 Delta Biotechnology Ltd Yeast strains and modified albumins
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5716808A (en) 1995-11-09 1998-02-10 Zymogenetics, Inc. Genetic engineering of pichia methanolica
US5955349A (en) 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US6509313B1 (en) 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
CN1230997A (zh) 1996-07-17 1999-10-06 津莫吉尼蒂克斯公司 甲醇毕赤酵母的转化
US6274305B1 (en) 1996-12-19 2001-08-14 Tufts University Inhibiting proliferation of cancer cells
US6605699B1 (en) 1997-01-21 2003-08-12 Human Genome Sciences, Inc. Galectin-11 polypeptides
US7053190B2 (en) 1997-03-07 2006-05-30 Human Genome Sciences, Inc. Secreted protein HRGDF73
US7196164B2 (en) 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
US6506569B1 (en) 1997-05-30 2003-01-14 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR10
US5875969A (en) 1997-07-18 1999-03-02 The Toro Company Sprinkler with self cleaning bowl
US5948609A (en) 1997-12-03 1999-09-07 Carter; Daniel C. Oxygen-transporting albumin-based blood replacement composition and blood volume expander
CA2306554A1 (en) 1998-08-06 2000-02-17 Jin Po Lee Uric acid assay device with stabilized uricase reagent composition
US6444790B1 (en) 1998-12-23 2002-09-03 Human Genome Sciences, Inc. Peptidoglycan recognition proteins
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
EP2110381A1 (en) 1999-05-17 2009-10-21 ConjuChem Biotechnologies Inc. Long lasting fusion peptide inhibitors of viral infection
EE200200538A (et) 2000-03-22 2004-04-15 Octagene Gmbh Rekombinantsete verehüübimisfaktorite produtseerimine inimese rakuliinides
CA2405709A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
WO2002016411A2 (en) 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
WO2002022809A2 (en) 2000-09-15 2002-03-21 Coley Pharmaceutical Gmbh PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
US7615537B2 (en) 2000-10-25 2009-11-10 Genzyme Corporation Methods for treating blood coagulation disorders
WO2002043658A2 (en) 2000-11-06 2002-06-06 The Jackson Laboratory Fcrn-based therapeutics for the treatment of auto-immune disorders
WO2002046227A2 (en) 2000-12-07 2002-06-13 Eli Lilly And Company Glp-1 fusion proteins
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
CA2444632A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
AUPR446701A0 (en) 2001-04-18 2001-05-17 Gene Stream Pty Ltd Transgenic mammals for pharmacological and toxicological studies
DE60231804D1 (de) 2001-05-25 2009-05-14 Inst Nat Sante Rech Med Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
EP1406917A4 (en) 2001-06-15 2007-11-14 New Century Pharmaceuticals HUMAN ANALYTICAL MODELS FOR THE EVALUATION OF MEDICINAL PRODUCTS AND FOR TOXICOLOGICAL AND IMMUNOGENIC EXAMINATIONS
ATE375388T1 (de) 2001-07-27 2007-10-15 Us Gov Health & Human Serv Systeme zur stellengerichteten in-vivo-mutagenese mit oligonukleotiden
CN1405182A (zh) 2001-08-10 2003-03-26 中国人民解放军军事医学科学院生物工程研究所 血清白蛋白与粒细胞集落刺激因子的融合蛋白
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
US20080167238A1 (en) 2001-12-21 2008-07-10 Human Genome Sciences, Inc. Albumin Fusion Proteins
JP2005530484A (ja) 2002-02-07 2005-10-13 デルタ バイオテクノロジー リミテッド アルブミン融合抗血管形成ペプチド
AU2003210806A1 (en) 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
WO2003102136A2 (en) 2002-05-30 2003-12-11 Human Genome Sciences, Inc. Antibodies that specifically bind to neurokinin b
CN1241946C (zh) 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
GB0217347D0 (en) 2002-07-26 2002-09-04 Univ Edinburgh Novel albumins
EP1572955A2 (en) 2002-08-02 2005-09-14 Human Genome Sciences, Inc. Antibodies against c3a receptor
AU2003295644A1 (en) 2002-11-19 2004-07-22 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
CA2516409A1 (en) 2003-02-17 2004-08-26 Upperton Limited Conjugates for medical imaging comprising carrier, targeting moiety and a contrast agent
GB0305989D0 (en) 2003-03-15 2003-04-23 Delta Biotechnology Ltd Agent
US20070041987A1 (en) 2003-03-19 2007-02-22 Daniel Carter Fragments or polymers of albumin with tunable vascular residence time for use in therapeutic delivery and vaccine development
EP2006298A3 (en) 2003-04-15 2009-04-22 Xenon Pharmaceuticals Inc. Juvenile hemochromatosis gene (HFE2A), expression products and uses thereof
US20050079546A1 (en) 2003-05-01 2005-04-14 Dasa Lipovsek Serum albumin scaffold-based proteins and uses thereof
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
US20080308744A1 (en) 2003-11-18 2008-12-18 Beth Israel Deaconess Medical Center Serum Albumin Conjugated to Fluorescent Substances for Imaging
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
GB0329722D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Modified plasmid and use thereof
JP4649954B2 (ja) 2003-12-26 2011-03-16 ニプロ株式会社 抗菌作用が増強されたアルブミン
US7166577B2 (en) 2003-12-26 2007-01-23 Nipro Corporation Albumin having enhanced antimicrobial activity
KR100671005B1 (ko) 2004-01-15 2007-01-18 고려대학교 산학협력단 Ｐａｈ 노출 여부 진단용 바이오 마커 단백질
MXPA06009072A (es) 2004-02-09 2007-03-29 Human Genome Sciences Inc Proteinas de fusion de albumina.
RU2369404C2 (ru) 2004-02-09 2009-10-10 Хьюман Дженом Сайенсиз, Инк. Слитые белки альбумина
JP4492156B2 (ja) 2004-03-03 2010-06-30 ニプロ株式会社 血清アルブミンドメインを含む蛋白質
US20060018859A1 (en) 2004-07-16 2006-01-26 Carter Daniel C Modified human serum albumin with reduced or eliminated affinity to chemical or biological contaminants at Cys 34
US20060051859A1 (en) 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs
NZ580115A (en) 2004-09-23 2010-10-29 Genentech Inc Cysteine engineered antibody light chains and conjugates
WO2006066595A2 (en) 2004-12-22 2006-06-29 Novozymes A/S Recombinant production of serum albumin
EP1831375B1 (en) 2004-12-23 2014-07-16 Novozymes Biopharma DK A/S Gene expression technique
WO2006073195A1 (ja) 2005-01-07 2006-07-13 Biomarker Science Co., Ltd 糖尿病の予知・診断方法および糖尿病予知・診断用キット
US20060178301A1 (en) 2005-02-04 2006-08-10 Mathias Jurs Albumin-fused ciliary neurotrophic factor
US20100266530A1 (en) 2005-04-29 2010-10-21 The Jackson Laboratory FcRN ANTIBODIES AND USES THEREOF
GB0512707D0 (en) 2005-06-22 2005-07-27 Delta Biotechnology Ltd Gene expression technique
JP2009504157A (ja) 2005-08-12 2009-02-05 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
US8008257B2 (en) 2005-10-20 2011-08-30 University Of Ottawa Heart Institute ANF fusion proteins
WO2007071068A1 (en) 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
WO2007112940A2 (en) 2006-03-31 2007-10-11 Ablynx N.V. Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same
AU2007258609B2 (en) 2006-06-07 2013-01-24 Human Genome Sciences, Inc. Albumin fusion proteins
JP5800458B2 (ja) 2006-06-14 2015-10-28 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 血液凝固因子を有するタンパク質分解によって切断可能な融合タンパク質
CA2657277C (en) 2006-07-13 2015-11-24 Upperton Limited Process for preparing particles of proteinaceous material
JP4983148B2 (ja) 2006-08-18 2012-07-25 ニプロ株式会社 糖鎖含有アルブミン、その製造方法およびその用途
AU2007292903B2 (en) 2006-09-08 2012-03-29 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
US20100129846A1 (en) 2006-12-07 2010-05-27 Power3 Medical Products, Inc. Isoform specificities of blood serum proteins and their use as differentially expressed protein biomarkers for diagnosis of breast cancer
JP2010535484A (ja) 2007-08-08 2010-11-25 ノボザイムス バイオファーマ デーコー アクティーゼルスカブ トランスフェリン変異体と複合体
WO2009061853A2 (en) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
CA2611540C (en) 2007-11-09 2017-05-30 Nipro Corporation Sugar chain-containing albumin as a drug carrier to the liver
EP3211010A1 (en) 2007-12-21 2017-08-30 Medimmune Limited Binding members for interleukin-4 receptor alpha (il-4r) - 173
CA2721093A1 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
WO2009134808A2 (en) 2008-04-28 2009-11-05 President And Fellows Of Harvard College Supercharged proteins for cell penetration
MX2011000655A (es) 2008-07-18 2011-03-21 Oragenics Inc Composiciones para la deteccion y tratamiento de cancer colorrectal.
WO2010059315A1 (en) 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
NZ606480A (en) 2008-12-05 2014-08-29 Abraxis Bioscience Llc Albumin binding peptide-mediated disease targeting
CN102307905B (zh) 2008-12-10 2015-11-25 斯克利普斯研究院 利用化学反应性非天然氨基酸产生载体-肽偶联物
EP2396347B1 (en) 2009-02-11 2017-04-12 Albumedix A/S Albumin variants and conjugates
KR20120018762A (ko) 2009-04-08 2012-03-05 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 제어된 혈청 약동학적 특성을 갖는 인간 단백질 스캐폴드
JP2012525146A (ja) 2009-04-28 2012-10-22 プレジデント アンド フェロウズ オブ ハーバード カレッジ 細胞透過のための過剰に荷電されたタンパク質
WO2010138814A2 (en) 2009-05-29 2010-12-02 The Brigham And Women's Hospital, Inc. Disrupting fcrn-albumin interactions
EP2437767B1 (en) 2009-06-01 2015-07-08 MedImmune, LLC Molecules with extended half-lives and uses thereof
KR101286721B1 (ko) 2009-06-05 2013-07-16 한국과학기술연구원 폴리-시스테인 펩티드 융합 재조합 알부민 및 이의 제조방법
CA2768360A1 (en) 2009-07-20 2011-01-27 National Cheng Kung University Polypeptides selective for .alpha.v.beta.3 integrin conjugated with a variant of human serum albumin (hsa) and pharmaceutical uses thereof
US20120269765A1 (en) 2009-07-24 2012-10-25 Garcia K Christopher Cytokine compositions and methods of use thereof
EP2889624B1 (en) 2009-08-10 2018-10-03 UCL Business PLC Reversible covalent linkage of functional molecules
US20110172398A1 (en) 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
AU2010303166A1 (en) 2009-10-10 2012-05-24 Eleven Biotherapeutics, Inc. IL-17 family cytokine compositions and uses
CN102741280B (zh) 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 白蛋白变体
KR20120130752A (ko) 2009-12-23 2012-12-03 내셔널 타이완 유니버시티 혈관신생-관련된 안질환의 치료를 위한 조성물 및 방법
CN101875693B (zh) 2010-01-22 2012-07-18 成都正能生物技术有限责任公司 具备抗血管生成活性的白蛋白变异体及其制备方法
ES2678144T3 (es) * 2010-02-16 2018-08-09 Medimmune, Llc Composiciones relacionadas con SAH y métodos de uso
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
US9238080B2 (en) 2010-05-21 2016-01-19 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
WO2011161127A1 (en) 2010-06-21 2011-12-29 Medimmune, Llc Protease variants of human neprilysin
US9012609B2 (en) 2010-08-13 2015-04-21 Glaxosmithkline Intellectual Property Development Limited Anti-serum albumin binding variants
EP2635598A1 (en) 2010-11-01 2013-09-11 Novozymes Biopharma DK A/S Albumin variants
CA2826683A1 (en) * 2011-02-15 2012-08-23 Medimmune, Llc Hsa-related compositions and methods of use
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
CN104011072B (zh) 2011-05-05 2018-10-12 阿尔布梅迪克斯医疗有限公司 白蛋白变体
US9353172B2 (en) 2011-07-18 2016-05-31 Arts Biologics A/S Long acting biologically active luteinizing hormone (LH) compound
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
AU2013234299B2 (en) 2012-03-16 2017-06-22 Albumedix Ltd. Albumin variants
WO2014005596A1 (en) 2012-07-03 2014-01-09 Aarhus Universitet Modified payload molecules and their interactions and uses
GB2512156A (en) 2012-11-08 2014-09-24 Novozymes Biopharma Dk As Albumin variants
EP2956002B1 (en) 2013-02-16 2017-09-06 Albumedix A/S Pharmacokinetic animal model
WO2014179657A1 (en) 2013-05-03 2014-11-06 Eleven Biotherapeutics, Inc. Albumin variants binding to fcrn
US20160222087A1 (en) 2013-09-13 2016-08-04 Novozymes Biopharma Dk A/S Albumin variants
EP3063171B1 (en) 2013-11-01 2019-07-24 University Of Oslo Albumin variants and uses thereof
US9847012B2 (en) 2014-07-07 2017-12-19 Google Llc Meal-based medication reminder system
JP7007261B2 (ja) 2015-08-20 2022-01-24 アルブミディクス リミティド アルブミン変異体及びコンジュゲート

Also Published As

Publication number Publication date
US20180334491A1 (en) 2018-11-22
EP2780364A2 (en) 2014-09-24
WO2013075066A2 (en) 2013-05-23
US10711050B2 (en) 2020-07-14
US20140315817A1 (en) 2014-10-23
WO2013075066A3 (en) 2013-07-04

Similar Documents

Publication Publication Date Title
HK1200842A1 (zh) 具有改進半衰期和其他特性的蛋白質
HUS2100034I1 (hu) ANGPTL3-ellenes antitestek és alkalmazásaik
IL288203A (en) Meditops and Meditop binding antibodies and their use
IL260045B (en) Polypeptide structures and their uses
IL281250A (en) Anti-PHF-tau antibodies and uses thereof
ZA201305123B (en) Modified antibody with improved half-life
IL232399A0 (en) Anti-2fgfr antibodies and their use
IL224441B (en) Antibodies with modified isoelectric points
EP2756094A4 (en) ANTI-B7-H4 ANTIBODIES AND USES THEREOF
HK1199842A1 (zh) 抗涎免凝集素- 抗體及其用途
EP2756095A4 (en) BIOMARKERS RELATED TO INSULIN RESISTANCE AND METHOD OF USE THEREOF